Methoxy Polyethylene Glycol-Epoetin Beta Generics Suppliers & Bulk Manufacturers
Available Forms: Solution for Injection
Available Strengths: 25–250 mcg
Reference Brands: Mircera® (US &EU)
Category:
Nephrology
Methoxy Polyethylene Glycol-Epoetin Beta, marketed as Mircera®, is a long-acting ESA used to treat anemia in CKD patients, both on and off dialysis. Approved in the EU and US, it is available as a solution for injection in prefilled syringes or vials, with extended dosing intervals (biweekly or monthly).
Methoxy Polyethylene Glycol-Epoetin Beta Generics is available in Solution for Injection
and strengths such as 25–250 mcg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Methoxy Polyethylene Glycol-Epoetin Beta Generics is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Methoxy Polyethylene Glycol-Epoetin Beta Generics can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Methoxy Polyethylene Glycol-Epoetin Beta, branded as Mircera®, is an advanced erythropoiesis-stimulating agent (ESA) designed for the treatment of anemia in chronic kidney disease (CKD) patients. Its long half-life enables once-monthly or biweekly dosing, improving compliance and reducing injection frequency. Approved in both the EU and US, Mircera® is widely used in dialysis and non-dialysis CKD populations. Available as prefilled syringes and vials in multiple strengths, it is an essential product in nephrology care. A strategic asset for pharmaceutical B2B partners, it offers opportunities in licensing, distribution, and hospital tenders across regulated markets with growing CKD treatment needs.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing